Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: KeithsLite who wrote (13852)	12/16/2004 12:29:11 PM
From: spinoza	Read Replies (1) \| Respond to of 14101

Thanks for the update on the formularies, I believe this has always been a big stumbling block to MD's using the drug but also what drugs they consciously make an effort to remember. Solvay may need to lower the price of Pennsaid to make a compelling pharmacoeconomic model needed for formulary approval. Hopefully the company would support this move and anything else necessary to get Pennsaid moving again.

To: KeithsLite who wrote (13852)	12/19/2004 8:43:34 PM
From: Mark Bartlett	Read Replies (3) \| Respond to of 14101

Jim, I thought russett said that Celebrex was different and would not act on the heart in the same as Vioxx .... this was not a class effect, he said. Seems the great spud man was wrong. Think of all those he must have cajoled into continuing to holding Pfizer stock ... I wonder if he feels guilty about it. The thought of russett being wrong brings a tear to my eye .... yeah, right. What do you have to say for yourself spud boy. MB